Exscientia to discuss role of AI in small molecule drug discovery
SMi reports: Andrew Hopkins, Chief Executive at Exscientia to discuss the role of Artificial Intelligence in small molecule drug discovery at SMi’s Drug Discovery conference in March 2018
The world’s leading drug companies are turning to artificial intelligence to improve the hit-and-miss business of finding new medicines, with GlaxoSmithKline unveiling a new $43 million deal in the field on Sunday.“Many large pharma companies are starting to realize the potential of this approach and how it can help improve efficiencies,” said Andrew Hopkins, Chief Executive of privately owned Exscientia.Hopkins said Exscientia’s AI system could deliver drug candidates in roughly one-quarter of the time and at one-quarter of the cost of traditional approaches [Source: Reuters] Hear from Andrew Hopkins, Chief Executive Officer of Exscientia at Drug Discovery conference in London next March where he will discuss “Transforming Small Molecule Drug Discovery using Artificial Intelligence”. His presentation will cover the following:
- Exscientia’s automated design process mimics human creativity by designing molecules which integrate the wealth of available data
- Discover how Exscientia’s AI is delivering pre-clinical candidates with exception productivity
- Learn how artificial intelligence and human expertise can be best combined to re-design the drug discovery process
- The potential of AI to increase the capital efficacy of R&D
Andrew Hopkins, Exscientia will be joined by Mark Davies, Vice President, Biomedical Informatics, Benevolent AI, Claus Bendtsen, Executive Director & Head of Quantitative Biology, AstraZeneca, Gisbert Schneider, Professor, Chair for Computer-Assisted Drug Design, ETH Zurich. These expert speakers will all presebt on the new role of artificial intelligence in drug discovery. Visit our website and download the brochure for the full agenda.
Alongside the two-day conference, there will be two pre-conference workshops taking place on Tuesday 20th March 2018. The morning session will be led by Nicolas Clare, Technical Project Leader at Axol Bioscience. He will discuss Induced Pluripotent Stem Cell Derived Models and their use in Drug Discovery. The workshop is aimed at those who would like to understand the revolutionary biological technique of creating induced pluripotent stem cells (Ipsc) from any source material, differentiating them into different cell lineages and their use in drug discovery, either as healthy controls or disease models.
The afternoon workshop will be led by Emanuela Cuomo, Associate Principal Scientist at AstraZeneca who will provide an overview of CRISPR/Cas technologies and how they are applied to drug development. Specific examples will illustrate how genome editing is used in AstraZeneca pipeline to improve target identification and validation; also how it can be used to predict drug resistance and direct drug optimisation.
For more details about the conference and registration information, visit www.drug-discovery.co.uk
For sponsorship and exhibition queries please contact Alia Malick at email@example.com. For delegate queries please contact Kieran Ronaldson at firstname.lastname@example.org. For media queries please contact Natasha Boumediene at email@example.com.
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk